MGMT and central nervous system cancer: The absence of MGMT promoter methylation is an additional negative prognostic factor in TERT mutated GBM [8, 15, 21–24], and assessment of MGMT promoter methylation status assists in better defining prognosis for patients with gliomas, due to the role of this feature as a predictive marker of therapeutic efficacy [25].